Application of Immunotherapy in Hepatocellular Carcinoma

被引:11
作者
Miao, Lele [1 ,2 ]
Zhang, Zhengchao [1 ,2 ]
Ren, Zhijian [1 ,2 ]
Li, Yumin [1 ,2 ]
机构
[1] Second Hosp Lanzhou Univ, Dept Gen Surg, Lanzhou, Peoples R China
[2] Second Hosp Lanzhou Univ, Key Lab Digest Syst Tumors Gansu Prov, Lanzhou, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2021年 / 11卷
关键词
hepatocellular carcinoma; immunotherapy; immune checkpoint inhibitors; tumor vaccines; adoptive cell therapy; IMMUNE CHECKPOINT INHIBITORS; T-CELLS; ADOPTIVE IMMUNOTHERAPY; ACQUIRED-RESISTANCE; ALPHA-FETOPROTEIN; OPEN-LABEL; ANTITUMOR-ACTIVITY; CLINICAL-TRIAL; PHASE-III; CANCER;
D O I
10.3389/fonc.2021.699060
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Hepatocellular carcinoma is one of the most common malignancies globally. It not only has a hidden onset but also progresses rapidly. Most HCC patients are already in the advanced stage of cancer when they are diagnosed, and have even lost the opportunity for surgical treatment. As an inflammation-related tumor, the immunosuppressive microenvironment of HCC can promote immune tolerance through a variety of mechanisms. Immunotherapy can activate tumor-specific immune responses, which brings a new hope for the treatment of HCC. At the present time, main immunotherapy strategies of HCC include immune checkpoint inhibitors, tumor vaccines, adoptive cell therapy, and so on. This article reviews the application and research progress of immune checkpoint inhibitors, tumor vaccines, and adoptive cell therapy in the treatment of HCC.
引用
收藏
页数:15
相关论文
共 146 条
  • [1] [Anonymous], 2017, Cancer Discov, V7, pOF3, DOI 10.1158/2159-8290.CD-NB2017-138
  • [2] Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ)
    Bang, Yung-Jue
    Golan, Talia
    Dahan, Laetitia
    Fu, Siqing
    Moreno, Victor
    Park, Keunchil
    Geva, Ravit
    De Braud, Filippo
    Wainberg, Zev A.
    Reck, Martin
    Goff, Laura
    Laing, Naomi
    Mi, Gu
    Oliveira, Joana M.
    Wasserstrom, Heather
    Lin, Chia-Chi
    [J]. EUROPEAN JOURNAL OF CANCER, 2020, 137 : 272 - 284
  • [3] Glypican-3-Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma
    Batra, Sai Arun
    Rathi, Purva
    Guo, Linjie
    Courtney, Amy N.
    Fleurence, Julien
    Balzeau, Julien
    Shaik, Rahamthulla S.
    Nguyen, Thao P.
    Wu, Meng-Fen
    Bulsara, Shaun
    Mamonkin, Maksim
    Metelitsa, Leonid S.
    Heczey, Andras
    [J]. CANCER IMMUNOLOGY RESEARCH, 2020, 8 (03) : 309 - 320
  • [4] CTLA-4 and PD-1 Pathways Similarities, Differences, and Implications of Their Inhibition
    Buchbinder, Elizabeth I.
    Desai, Anupam
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2016, 39 (01): : 98 - 106
  • [5] Dendritic cells in cancer immunotherapy clinical trials: are we making progress?
    Butterfield, Lisa H.
    [J]. FRONTIERS IN IMMUNOLOGY, 2013, 4
  • [6] Alpha fetoprotein DNA prime and adenovirus boost immunization of two hepatocellular cancer patients
    Butterfield, Lisa H.
    Economou, James S.
    Gamblin, T. Clark
    Geller, David A.
    [J]. JOURNAL OF TRANSLATIONAL MEDICINE, 2014, 12
  • [7] In situ Vaccination by Direct Dendritic Cell Inoculation: The Coming of Age of an Old Idea?
    Castiello, Luciano
    Arico, Eleonora
    D'Agostino, Giuseppina
    Santodonato, Laura
    Belardelli, Filippo
    [J]. FRONTIERS IN IMMUNOLOGY, 2019, 10
  • [8] Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma
    Chen, Dong-Ping
    Ning, Wan-Ru
    Jiang, Ze-Zhou
    Peng, Zhi-Peng
    Zhu, Ling-Yan
    Zhuang, Shi-Mei
    Kuang, Dong-Ming
    Zheng, Limin
    Wu, Yan
    [J]. JOURNAL OF HEPATOLOGY, 2019, 71 (02) : 333 - 343
  • [9] Sirtuin2 enhances the tumoricidal function of liver natural killer cells in a mouse hepatocellular carcinoma model
    Chen, Ming
    Xu, Min
    Zhu, Chengliang
    Wang, Hongling
    Zhao, Qiu
    Zhou, Feng
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2019, 68 (06) : 961 - 971
  • [10] Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma
    Chew, Valerie
    Lee, Yun Hua
    Pan, Lu
    Nasir, Nurul J. M.
    Lim, Chun Jye
    Chua, Camillus
    Lai, Liyun
    Hazirah, Sharifah Nur
    Lim, Tony Kiat Hon
    Goh, Brian K. P.
    Chung, Alexander
    Lo, Richard H. G.
    Ng, David
    Filarca, Rene L. F.
    Albani, Salvatore
    Chow, Pierce K. H.
    [J]. GUT, 2019, 68 (02) : 335 - 346